Loading...
Market
Percentage of immunocompromised receiving additional doses by June 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
CDC vaccination reports and studies on immunocompromised populations
Story
CDC Recommends Second 2024-2025 COVID-19 Vaccine Dose for Seniors and Immunocompromised
Oct 24, 2024, 03:23 PM
The Centers for Disease Control and Prevention (CDC) has recommended a second dose of the 2024-2025 COVID-19 vaccine for individuals aged 65 and older, as well as those with moderately to severely weakened immune systems. This recommendation, made by the Advisory Committee on Immunization Practices (ACIP) on October 23, 2024, aims to enhance protection for these vulnerable groups. The CDC advises that the second dose should be administered six months after the initial dose, establishing a 6-month vaccine cadence. The policy is specific to the 2024-2025 period and includes provisions for immunocompromised individuals to receive additional doses in consultation with their clinicians.
View original story
Similar markets
Less than 40% • 25%
40% to 60% • 25%
60% to 80% • 25%
More than 80% • 25%
GeoVax COVID-19 vaccine • 33%
Moderna mRNA influenza vaccine • 33%
Pfizer COVID-19 vaccine • 33%
Less than 30% • 25%
30% to 50% • 25%
51% to 70% • 25%
More than 70% • 25%
Increase to 25% or more • 25%
Increase to 20-24% • 25%
Remain below 20% • 25%
Decrease further • 25%
Yes • 50%
No • 50%
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%
65-74 • 25%
75-84 • 25%
85 and older • 25%
Immunocompromised individuals • 25%
Yes • 50%
No • 50%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
Yes • 50%
No • 50%